Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use

Advances in Therapy

Volumn 30, Issue 5, 2013, Pages 472-486

  Jain, Rakesh ^a   Babcock, Thomas ^b   Burtea, Teodor ^c   Dirks, Bryan ^b   Adeyi, Ben ^b   Scheckner, Brian ^b   Lasser, Robert ^b   Renna, John ^b   Duncan, Don ^d  

^a R/D Clinical Research Inc   (United States)

^b SHIRE   (United States)

^c Shire Canada   (Canada)

^d BC Interior ADHD Clinic   (Canada)

Author keywords

Attention deficit hyperactivity disorder; Children; Efficacy; Lisdexamfetamine dimesylate; Methylphenidate; Psychiatry; Safety; Stimulants

Indexed keywords

LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; SINUS ARREST; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; WEIGHT REDUCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PRODRUGS; TREATMENT OUTCOME;

EID: 84879219513     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0027-2     Document Type: Article

References (35)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942-8.
2. Rader R, McCauley L, Callen EC. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. Am Fam Physician. 2009;79:657-65.
3. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA. 1998;279:1100-7.
4. Dopheide JA. ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients. Am J Health Syst Pharm. 2005;62:1502-9.
5. Heishman SJ, Henningfield JE. Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology (Berl). 1991;103:436-42.
6. Heron C, Costentin J, Bonnet JJ. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier. Eur J Pharmacol. 1994;264:391-8.
7. Hess EJ, Collins KA, Wilson MC. Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J Neurosci. 1996;16:3104-11.
8. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009;57:608-18.
9. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642-57.
10. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000;3:200-11.
11. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141-55.
12. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-27.
13. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450-63.
14. Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.
15. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970-6.
16. Findling RL, Ginsberg LD, Jain R, Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19:649-62.
17. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr. 2008;13:614-20.
18. Mares D, McLuckie A, Schwartz M, Saini M. Executive function impairments in children with attention-deficit hyperactivity disorder: Do they differ between school and home environments? Can J Psychiatry. 2007;52:527-34.
19. Strine TW, Lesesne CA, Okoro CA, et al. Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder. Prev Chronic Dis. 2006;3:A52.
20. Gioia GA, Isquith PK, Guy SC, Kenworthy L. BRIEF: Behavior Rating Inventory of Executive Function: professional manual. Lutz, FL: Psychological Assessment Resources Inc, 2000. Child Neuropsychol. 2000;6:235-8.
21. Gioia GA, Isquith PK, Retzlaff PD, Espy KA. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002;8:249-57.
22. Kratochvil CJ, Faries D, Vaughan B, et al. Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects. J Child Adolesc Psychopharmacol. 2007;17:51-62.
23. Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull. 1998;34:47-53.
24. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord. 2006;10:92-111.
25. DuPaul GJ, Power T, Anastopoulos A, Reid R. ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. New York: Guilford Press; 1998.
26. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, MD; 1976. p. 218-22.
27. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: diagnostic and statistical manual of mental disorders DSM-IV-TR, 4th ed. Washington, DC: American Psychiatric Association; 2000. p. 85-93.
28. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892-908.
29. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40:168-79.
30. Wigal T, Brams M, Gasior M, Gao J, Giblin J. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med. 2011;123:169-76.
31. Ginsberg L, Katic A, Adeyi B, et al. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. Curr Med Res Opin. 2011;27:1097-107.
32. Jain R, Babcock T, Burtea T, et al. Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysis. Child Adolesc Psychiatry Ment Health. 2011;5:35.
33. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta® methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.
34. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention-deficit/hyperactivity disorder. Can J Clin Pharmacol. 2006;13:e50-62.
35. Brown TE. ADD/ADHD and impaired executive function in clinical practice. Curr Psychiatry Rep. 2008;10:407-11.